Impact Of Sitagliptin On The Inflammatory Factors In The Type 2 Diabetes Early Macrovascular Complications

[Background]Type 2 diabetes mellitus(T2DM) is a major cause of disability and death due to its complications, which is a major cause of disability.Because the atherosclerosis in the large vascular disease has brought heavy pressure on the development of society.So, for newly diagnosed patients with type 2 diabetes mellitus should be in the early positive for intervention of blood sugar, formulate suitable glucose lowering scheme, as far as possible to reduce the risk factors for the occurrence of hypoglycemia and macrovascular complications, in preventing and slowing in diabetes progression and large blood vessel complications occurrence and development has important significance.And macrovascular disease is a chronic inflammatory disease, its development and inflammatory factor in the relationship between very close, especially high sensitivity C-reactive protein(hs CRP), homocysteine(Hcy) were the risk factors and development plays an important role in its.Sitagliptin, as a two peptide based peptide enzyme-4(DPP-4) inhibitor, is currently a second-line drug treatment of diabetes, which can not only control blood sugar, some scholars believe that it can bring cardiovascular benefit.This has opened up a new direction for the diabetes macrovascular complications. [Objective]1.To observe the blood glucose level in patients with type 2 diabetic early macrovascular complications who were treated with for sitagliptin a period of time.2.To observe the changes of plasma homocysteine(Hcy), High-sensitivity C reactive protein(hs-CRP), fasting insulin and insulin resistance index(HOMA-IR) in patients with type 2 diabetes before and after treatment with sitagliptin. [Methods]Select 13 cases with type 2 diabetic early macrovascular complicatio ns who hospitalized in the Department of Endocrinology ward of Fujian MedicalUniversity Affiliated Union Hospital from July 2015 to February 2016,the average age(49.8±10.6),the disease course(2.85±1.86),body Mass Index(BMI)(25.10± 2.85)kg/m2.Each patient is treated with sitagliptin 100mg/d for 12 weeks o n the basis of the original oral hypoglycemic agents,measured clinical data like t he height, weight, fasting blood glucose, glycosylated hemoglobin(HbA1c),trigly ceride(TG), cholesterin(CHOL), high density lipoprotein cholesterol(HDL-C), l ow density lipoprotein cholesterol(LDL-C), High-sensitivity C-reactive protein(hs-CRP), homocysteine(Hyc), intima-media thickness(IMT),fasting insulin(FINS),and compare the changes. [Result]Before and after sitagliptin treatment, blood glucose, homocysteine levels decreased significantly(P<0.05), hs-CRP, fasting insulin, insulin resistance index decreased, but there was no statistical difference(P>0.05) [Conclusion]1.Type 2 diabetic patients with early stage of large vascular lesions in patients with sitagliptin’s treatment can effectively control blood sugar.2.Sitagliptin can reduce the homocysteine(Hcy) level...